ClinicalTrials.gg
Not yet recruitingNCT07946120APHARIPEUpdated Nov 18, 2026

Perceived Autonomy in Performing Intravenous Injections for Patients With Severe or Moderate Hemophilia A Receiving Emicizumab

An observational study in Hemophilia A, sponsored by University Hospital, Caen. Not yet recruiting at 25 sites in 2 countries. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by University Hospital, Caen · Observational

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
450
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 158 studies in Hemophilia A with a site in France — 21 open to participants now, 34 under way, 15 of them phase 3. Hemophilia A · France.

Planned enrollment
12th of 63
450 · median 142
Started
2027
with 2 others
Observational
63 of 158
12 open now
Primary completion
2028-06
later than 24 of 33 live
Registered
158th of 158
by date

Among the 158 studies in Hemophilia A with a site in France, this one is the 12th largest by planned enrollment of the 63 observational ones that give a count, is one of 3 that started in 2027, is one of 63 observational ones, reaches primary completion later than 24 of the 33 other live ones, and was the 158th registered.

Hemophilia A

845 studies on the registry are indexed under Hemophilia A; 137 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

21 of the 158 studies in Hemophilia A with a site in France are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 88 Hemophilia A studies recruiting now, 52 (59%) set no upper age limit and 31 (35%) stop at 75 or younger; 56 take children under 18; 10 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 158 studies in Hemophilia A with a site in France, or all of them as a file.
02

Study summary

Hemophilia A is a rare inherited bleeding disorder caused by a deficiency in clotting factor VIII (severe if \<1%, moderate if 1% to 5%). Until the introduction of emicizumab (Hemlibra®), treatment relied exclusively on frequent intravenous (IV) infusions of clotting factor concentrates (FVIII or bypassing agents), allowing patients or their family caregivers to maintain technical skills and autonomy through regular practice.

Since 2018 (and 2023 for moderate hemophilia A), subcutaneous prophylactic treatment with emicizumab has drastically reduced bleeding episodes and, consequently, the frequency of IV infusions. However, IV injections remain necessary to treat acute breakthrough bleeds. The investigators hypothesize that previously autonomous patients or family caregivers may experience a gradual loss of skill and self-efficacy in performing IV injections while on emicizumab prophylaxis.

The APHARIPE study is a multicenter, non-interventional, exploratory study based on questionnaires administered to 450 previously autonomous patients with severe or moderate hemophilia A (or their family caregivers) receiving emicizumab, as well as their healthcare providers. Over an 18-month inclusion period, this study aims to assess perceived autonomy in performing IV injections, identify potential perception gaps between patients/caregivers and healthcare providers, evaluate the impact on acute bleed management and home emergency treatment storage, and guide future therapeutic education practices.

Read the detailed description

Hemophilia is a rare constitutional bleeding disorder. Severe hemophilia A corresponds to a severe factor VIII (FVIII) deficiency (\<1%), and moderate hemophilia A to an FVIII level between 1% and 5%. Both forms manifest as spontaneous or post-traumatic/surgical intra-articular bleeds (hemarthroses) or muscle hematomas, which can jeopardize functional prognosis if recurrent.

Until April 2018, the treatment of severe and moderate hemophilia A was exclusively substitutive, relying on intravenous (IV) injections of clotting factor concentrates (FVIII, or bypassing agents such as rFVIIa or aPCC for patients with anti-FVIII inhibitors). Used both prophylactically (2 to 3 IV infusions per week) and on-demand for acute bleeds, this regimen enabled most patients-or family caregivers for younger children-to acquire and maintain autonomy in performing IV injections through frequent practice.

Since April 2018 for patients with inhibitors, March 2020 for severe hemophilia A without inhibitors, and January 2023 for moderate hemophilia A, subcutaneous prophylaxis with the monoclonal antibody emicizumab (Hemlibra®) has been available. While emicizumab converts the bleeding phenotype to that of mild hemophilia, it is strictly prophylactic; IV clotting factor infusions remain required in the event of breakthrough bleeding. Because bleeding events become very rare under emicizumab, the frequency of IV injections drops sharply.

The investigators hypothesize that patients (or family caregivers) who were previously autonomous in performing IV clotting factor infusions progressively lose technical competence and/or self-efficacy during emicizumab prophylaxis. APHARIPE is a multicenter, exploratory, non-interventional questionnaire-based study designed to evaluate patients' and caregivers' perceived loss of autonomy. Healthcare providers caring for this population will also be surveyed to assess potential perception gaps regarding the impact of this loss of autonomy on overall patient management.

The study aims to include 450 patients (or family caregivers) with severe or moderate hemophilia A treated with emicizumab who were previously autonomous for IV injections, over an 18-month recruitment period. Findings will help identify specific difficulties, question the relevance of ongoing IV injection training, assess the impact on acute bleed management and the need to keep emergency treatments at home, and ultimately optimize patient care pathways and therapeutic education practices

03

Conditions studied

  • Hemophilia A

Browse trials for

Keywords

  • Severe and moderate hemophilia A
  • Perceived autonomy
  • Intravenous injections
  • Emicizumab
  • Therapeutic education
  • Self-administration
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population consists of adult and minor patients with severe (FVIII \<1%) or moderate (FVIII 1%-5%) hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year-or parent caregivers (excluding healthcare professionals) for non-autonomous minor patients-who were previously autonomous in performing intravenous clotting factor injections prior to emicizumab initiation. Healthcare professionals (physicians and nurses) involved in the care of these patients will also be enrolled. Participants will be recruited during routine clinical follow-up visits across participating French hemophilia treatment centers

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For autonomous adult patients (patient enrolled in the study):

  • Adult patient (>= 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained

For autonomous pediatric/minor patients (patient enrolled in the study):

  • Minor patient (\< 18 years old) with severe or moderate hemophilia A
  • Receiving prophylactic treatment with emicizumab for more than 1 year
  • Patient previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Patient non-opposition obtained
  • Non-opposition obtained from parents or legal guardians

For non-autonomous pediatric/minor patients (family caregiver enrolled in the study):

  • Parent caregiver of a child with severe or moderate hemophilia A receiving prophylactic treatment with emicizumab for more than 1 year
  • Parent previously autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation
  • Parent caregiver non-opposition obtained

For healthcare providers:

  • Physician, nurse, or healthcare professional involved in the care of patients with severe or moderate hemophilia A at a participating center
  • Healthcare provider non-opposition obtained

Exclusion criteria

Exclusion Criteria:

For autonomous adult patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For autonomous pediatric/minor patients:

- Patient not autonomous in performing intravenous injections of clotting factor concentrates prior to emicizumab initiation

For non-autonomous pediatric/minor patients:

- Parent caregiver who is a healthcare professional

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
450 participants (estimated)
Patient registry
No

Groups and cohorts

  • Patients or Family Caregivers

    Patients with severe or moderate hemophilia A (or family caregivers for pediatric) receiving emicizumab prophylaxis who were previously autonomous in performing intravenous clotting factor injections. Participants will complete a structured questionnaire assessing their perceived autonomy and self-efficacy

  • Healthcare Providers

    Healthcare professionals (physicians, nurses) caring for patients with hemophilia A at participating centers. Participants will complete a specific questionnaire evaluating their perception of patients' potential loss of autonomy for intravenous injections and its impact on clinical management

06

What researchers measure

Primary outcomes

  1. Proportion of Patients or Family Caregivers Reporting a Perceived Loss of Autonomy for Performing Intravenous Clotting Factor Injections

    Assessed using Question 9 of the study-specific patient/caregiver questionnaire (4-point Likert scale: "not at all autonomous", "slightly autonomous", "moderately autonomous", "completely autonomous"). Responses of "not at all autonomous", "slightly autonomous", or "moderately autonomous" will be classified as a perceived loss of autonomy. Expressed as absolute frequency and percentage of respondents

    Time frame: At baseline (single questionnaire completion)

Secondary outcomes

  1. Frequency of Clotting Factor Concentrate Use Under Emicizumab Prophylaxis

    Absolute and relative frequency (percentage) of patients requiring intravenous clotting factor concentrates (FVIII or bypassing agents) while receiving emicizumab prophylaxis, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  2. Proportion of Patients Keeping Clotting Factor Concentrates at Home

    Percentage of patients who report having clotting factor concentrates (FVIII or bypassing agents) stored at home, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  3. Proportion of Patients or Caregivers Reporting Anticipated Difficulties With Performing a Future Intravenous Injection

    Percentage of patients or family caregivers who report experiencing or anticipating difficulties in performing a subsequent intravenous clotting factor injection, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  4. Types of Difficulties Encountered During Intravenous Clotting Factor Injections

    Categorization and percentage distribution of specific technical or psychological difficulties reported by patients or family caregivers when performing intravenous injections, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  5. Proportion of Patients or Caregivers Expressing a Need for Home Nursing Assistance

    Percentage of patients or family caregivers reporting the need for a community nurse (IDE) to perform repeated intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  6. Proportion of Patients Expressing a Need for a Therapeutic Patient Education Program

    Percentage of patients reporting the need for therapeutic education sessions to maintain their autonomy in performing intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  7. Proportion of Patients or Caregivers Expressing a Need for Initial Intravenous Injection Training

    Percentage of patients or family caregivers reporting the need for initial training to learn how to perform intravenous clotting factor injections, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  8. Frequency and Quantity of Unused Expired Clotting Factor Concentrates at Home

    Absolute and relative frequency (percentage) of patients having unused expired FVIII concentrates or bypassing agents at home, along with the total number of expired doses reported via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  9. Proportion of Patients or Caregivers Reporting an Impact of Perceived Loss of Autonomy on Bleeding Event Management

    Absolute and relative frequency (percentage) of patients or family caregivers reporting that their perceived loss of autonomy negatively affected the management of an acute bleeding episode, assessed via the patient/caregiver questionnaire

    Time frame: At baseline (single questionnaire completion)

  10. Proportion of Healthcare Providers Supporting the Maintenance of Patient or Caregiver Autonomy for Intravenous Injections

    Percentage of healthcare professionals who consider it necessary to maintain patients' or family caregivers' autonomy for intravenous administration of clotting factor concentrates, assessed via the healthcare provider questionnaire

    Time frame: At baseline (single questionnaire completion)

  11. Proportion of Healthcare Providers Supporting the Maintenance of Clotting Factor Concentrates at Home

    Percentage of healthcare professionals who consider it necessary to keep emergency clotting factor concentrates at patients' homes, assessed via the healthcare provider questionnaire

    Time frame: At baseline (single questionnaire completion)

  12. Proportion of Healthcare Providers Perceiving a Delay in Bleeding Management Due to Reduced Patient Autonomy

    Percentage of healthcare professionals who consider that a decreased sense of autonomy for performing intravenous injections delays the management of acute bleeding episodes, assessed via the healthcare provider questionnaire

    Time frame: At baseline (single questionnaire completion)

07

Study locations

25 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jun 2028, 17 months later.

Of 78 non-industry observational studies under Hemophilia A, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 96. This study's planned 17 months is below that.

Counting every sponsor, half of 131 studies reached it within 45 months; a quarter within 25 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 18, 2026
StartEst.
Jan 15, 2027
Primary completionEst.
Jun 30, 2028
CompletionEst.
Jun 30, 2028
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946120
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 15, 2027 (estimated)
Primary completion
Jun 30, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Nov 18, 2026

Study contacts

Nicolas GUERIN, Registered Nurse
Contact
guerin-n@chu-caen.fr
+ 33 2 31 06 52 10
Nicolas GUERIN, Registered Nurse
principal investigator · Centre Hospitalier Universitaire de Caen - Centre de Ressources et de Compétences Maladies Hémorragiques Rares

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion